More on RNXT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+12.5% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

RenovoRx (NQ:RNXT)
Delayed: 1.23 +0.03 (2.50%)
Prev. Close $1.20  
Open$1.20 
52 Wk High$ 
52 Wk Low$ 
Day High$1.29 
Day Low$1.18 
P/E N/A  
EPS$ 
Volume403,712 

Friends, Peers and Foes (?): CELC, ONCY, OSTX SLS (more...)

Oct 16, 2026 07:00 AM Form RW RenovoRx, Inc.
Oct 7, 2026 08:33 AM RenovoRx enrolls first patient in UVM-sponsored PRISM-TAMP trial
Oct 7, 2026 08:30 AM RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 2, 2026 05:01 PM Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Macfarlane K. Angela
Oct 2, 2026 05:00 PM Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Spiegel Robert J.
Oct 2, 2026 05:00 PM Form 4 RenovoRx, Inc. For: Oct 01 Filed by: RYAN UNA S
Oct 2, 2026 05:00 PM Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Marton Laurence
Oct 1, 2026 08:33 AM RenovoRx case series published on pancreatic cancer drug delivery
Oct 1, 2026 08:31 AM RenovoRx's drug-delivery device featured in peer-reviewed cancer study
Oct 1, 2026 08:30 AM RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
View All Articles

Entities mentioned with RNXT

View All Entities